Questions
What was Amylin Pharmaceuticals and why does it matter for Ozempic-type drugs?
Amylin was a San Diego biotech that developed Byetta (exenatide), the first approved GLP-1 receptor agonist, in 2005. The hosts argue the whole modern GLP-1 weight-loss boom traces back to its work, even though Amylin itself did not profit from it.
Where did exenatide come from?
It came from John Eng, a researcher at a Bronx VA hospital, who bought dried Gila monster venom from a Utah catalog for about $50 and in 1992 isolated a 39-amino-acid peptide called exendin-4. It stayed active for about 24 hours, unlike natural GLP-1, which is destroyed within minutes.
Why did Amylin fail commercially despite being first?
Byetta needed twice-daily injections, caused notable nausea, and was linked to pancreatitis warnings. Amylin also lost a head-to-head study to Novo's Victoza and built a costly sales force that a smaller company could not afford.
What was the 'poison put' in the Carl Icahn proxy fight?
It was a clause in Amylin's roughly $600 million of convertible notes that let holders demand repayment at full face value if most of the board was replaced by directors the old board had not approved. With the notes trading near 55 cents on the dollar, winning the fight could have pushed Amylin toward bankruptcy.
What happened to Amylin in the end?
Bristol-Myers Squibb agreed in June 2012 to buy Amylin for $31 a share, a deal worth over $7 billion, after the board had earlier rejected a $22 offer. Amylin ceased to exist as an independent company on August 8, 2012, and AstraZeneca discontinued Byetta in 2024.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
In December 1987 Garth Cooper published in PNAS that pancreatic deposits contained a previously unknown 37-amino-acid peptide, initially called diabetes-associated peptide and later named amylin.
“the deposits contained a previously unknown 37-amino acid peptide, which Cooper initially called diabetes-associated peptide, or DAP for short”
0:06:30 · Alex Kesin · Amylin discovery · 1987
Hybritech was founded in October 1978 by UC San Diego assistant professor Ivor Royston and Howard Birndorf, in the parking lot of the La Jolla Cancer Research Foundation.
“In October of 1978, a young UC San Diego assistant professor named Ivor Royston and his RA, Howard Burnduff, founded Hybritech in the parking lot of the La Jolla Cancer Research Foundation.”
0:08:57 · Alex Kesin · Hybritech founding · 1978
Eli Lilly acquired Hybritech in March 1986 for roughly half a billion dollars in cash and warrants.
“Lilly acquired Hybritech for approximately a half $1 billion in cash and warrants, enamored by the assay and the potential of MABS as a therapeutic modality.”
0:13:43 · Alex Kesin · Lilly acquisition · 1986
John Eng isolated the substance responsible for pancreatic enlargement from Gila monster venom and published it in the Journal of Biological Chemistry in 1992.
“in 1992, Eng finds it. He isolates what is causing this pancreatic enlargement and publishes it in the Journal of Biological Chemistry.”
0:23:15 · Alex Kesin · Exendin-4 discovery · 1992
John Eng's paper described exendin-4, a 39-amino-acid peptide that stayed active for about 24 hours instead of minutes.
“So in that JBC paper, Eng discovered a 39-aminoacid peptide called exendin-4.”
0:23:41 · Alex Kesin · Exendin-4 · 1992
After the VA declined to patent the discovery, John Eng filed a patent himself in 1993 at his own expense.
“Aang decided to file the patent for himself in 1993 using his own money.”
0:25:26 · Alex Kesin · Exenatide patent · 1993
Amylin Pharmaceuticals went public in January 1992, raising $56 million at $14 a share.
“Imelin ended up going public in January of 1992, raising $56 million at $14 a share.”
0:29:17 · Matthew Pech · IPO · 1992
In 1995 Amylin partnered with Johnson & Johnson's LifeScan subsidiary, which would share half of development costs and pay all pre-launch marketing costs for pramlintide.
“In that same year, they announced a new partnership with J &J, specifically their subsidiary LifeScan. Under those terms, J &J would share half of the development costs and pay all of the pre-launch marketing costs.”
0:31:02 · Alex Kesin · J&J partnership · 1995
In February 1998 Johnson & Johnson ended its partnership with Amylin after pramlintide trial results were weaker in type 2 diabetes than in type 1.
“Since type 2 diabetes is where the real money is at, J &J decides the juice isn't worth the squeeze.”
0:32:56 · Alex Kesin · J&J exit · 1998
After Amylin's stock collapsed in 1998, Joe Cook returned from retirement as CEO and cut about 75% of the staff.
“Cook comes out of retirement, that's how serious this is, to take over as CEO and immediately fires 75 % of the staff of Amylin to stop the bleeding.”
0:33:16 · Alex Kesin · Restructuring · 1998
In July 2001 an FDA advisory committee voted 8-1 against approving Symlin for type 1 diabetes and 6-3 against for type 2.
“The panel votes 8-1 against approving the drug for type 1 diabetes. They vote 6-3 against type 2.”
0:38:01 · Alex Kesin · FDA advisory committee · 2001
In September 2002 Eli Lilly signed a partnership with Amylin worth up to $600 million to co-market exenatide.
“Lily comes back to the table and signs a partnership deal with Amylin worth up to $600 million”
0:39:53 · Matthew Pech · Lilly partnership · 2002
The FDA approved Symlin (pramlintide) on March 16, 2005, as the first new class of type 1 diabetes medicine since insulin.
“It's approved, and it's now the first new class of medicines approved for type 1 diabetes since the discovery of insulin itself 80 years earlier.”
0:46:52 · Alex Kesin · Symlin approval · 2005
Amylin and Eli Lilly announced FDA approval of Byetta for type 2 diabetes in April 2005, the first GLP-1 receptor agonist approved.
“announced the FDA approval of Bayeda for folks with type 2 diabetes. It's the first GLP-1 receptor agonist ever approved for any indication.”
0:47:29 · Alex Kesin · Byetta approval · 2005
Byetta had sales of $75 million in its launch year and $430 million in 2006.
“Their first year, they grossed $75 million. This was their launch year. And then the year after that, in 2006, they grossed $430 million”
0:49:01 · Alex Kesin · Byetta sales · 2006
In the Amigo trials, nausea affected about 18% of placebo patients and almost 45% of exenatide patients.
“In the Amigo trials, placebo patients had an 18 % nausea rate, whereas the exanatide group was sitting at almost 45%.”
0:51:24 · Matthew Pech · Nausea rates
Carl Icahn pushed MedImmune to sell to AstraZeneca in 2007 and ImClone to sell to Eli Lilly in 2008, before turning to Amylin.
“In 2007, he had forced Metamune to sell itself to AstraZeneca. In 2008, he targeted ImClone and forced a sale to Eli Lilly.”
0:53:04 · Matthew Pech · Icahn track record · 2007
Carl Icahn's April 2009 letter said Amylin's sales, general and administrative expenses consumed nearly 60% of its sales, against an industry median the hosts put at 22%.
“He pointed out that Amylin's overhead, SG &A, Sales General Administrative, the expenses there were eating up nearly 60 % of their sales.”
0:54:00 · Matthew Pech · Icahn letter · 2009
In January 2009 Carl Icahn notified Amylin he would nominate five directors to its 12-person board while owning about 9% of the company.
“he intended to nominate five directors to the company's 12-person board. At that time, he owned about 9 % of the company.”
0:59:00 · Matthew Pech · Proxy fight · 2009
Amylin's roughly $600 million of convertible notes could be called at full face value if most of its board were replaced by directors not approved by the existing board.
“Amylin had almost $600 million in convertible notes outstanding. If the majority of the board was replaced by directors not approved by the existing board, note holders could immediately demand repayment at full face value.”
1:00:24 · Matthew Pech · Poison put · 2009
In the 2009 proxy vote, Kathleen Behrens and Alexander Denner were elected to Amylin's board and Joe Cook and James Wilson were ousted.
“Two dissident nominees, Kathleen Behrens from the Eastbourne Slate and Alexander Denner from the ICANN Slate, were elected to the board. Chairman Joe Cook and lead director James Wilson were ousted.”
1:04:16 · Matthew Pech · Proxy vote · 2009
In March 2011 a head-to-head study showed Novo Nordisk's Victoza outperformed Amylin's once-weekly Bydureon, and Amylin lost about a quarter of its stock value in a day.
“that head-to-head study actually showed the competitor's drug, Victoza, was better. The market's verdict was instantaneous. Amylin lost a quarter of its value in a single day.”
1:06:09 · Alex Kesin · Bydureon vs Victoza · 2011
To end its Byetta partnership, Amylin paid Eli Lilly $250 million up front and signed a secured note for up to $1.2 billion from future sales.
“They pay Eli Lilly $250 million in cash up front to sever the partnership nuts. But that's not all. They also sign a secured note promising to pay Lilly up to $1.2 billion from future sales.”
1:08:26 · Alex Kesin · Lilly split · 2011
On February 15, 2012, Bristol-Myers Squibb CEO Lamberto Andreotti offered $22 a share for Amylin, which the board rejected without disclosing it.
“He's calling with an offer to Amylin, $22 a share to buy the whole company. At the time, Amylin is trading around $14 to $16 a share.”
1:09:28 · Matthew Pech · BMS offer · 2012
AstraZeneca discontinued Byetta, the first approved GLP-1 drug, by 2024.
“by 2024, AZ had quietly discontinued Bayetta, the first CLIP-1 drug ever approved, citing, as you would guess, business reasons.”
1:13:09 · Matthew Pech · Byetta discontinued · 2024
Tirzepatide's extended C-terminal tail is not found in natural human GLP-1 and is taken from exenatide.
“its extended C-terminus is not found on natural human GLP-1. And you want to guess why? I'll give you three seconds. One, two, three. Well, it's actually taken directly from exenatide.”
1:39:11 · Alex Kesin · Tirzepatide structure